Regencell Bioscience Holdings Ltd (RGC, Financial) experienced a notable stock price increase of 5.00%. The stock is currently priced at $6.20 per share, with a trading volume of 21,227 shares and a turnover rate of 0.16%. The price fluctuation for the stock is reported at 4.91%.
Recent financial reports indicate that Regencell Bioscience has not generated any revenue, with a net loss of $4.30 million and an earnings per share (EPS) of -$0.33. The gross profit stands at -$745,588, and the price-to-earnings (P/E) ratio is -18.76. Currently, no institutional ratings are available for this stock in terms of buy, hold, or sell recommendations.
Within the pharmaceutical industry, where Regencell operates, the overall sector has seen an increase of 2.52%. Notable performers in the sector include Biofrontera Inc C/Wts 27/10/2026 (To Pur Com), Sunshine Biopharma Inc., and Akanda Corp., which have shown significant gains. Sunshine Biopharma Inc., Painreform Ltd., and Biofrontera Inc. are particularly active, with turnover rates of 55.37%, 37.29%, and 10.11%, respectively. Additionally, Sunshine Biopharma Inc., Akanda Corp., and Painreform Ltd. have demonstrated substantial price fluctuations of 29.51%, 23.87%, and 20.63%.
Regencell Bioscience Holdings Ltd is a bioscience company focusing on traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, particularly ADHD and autism spectrum disorder (ASD), as well as infectious diseases affecting the immune system.
